Congleton Jon

Director · Officer · MLYS, IMUX, AVLN

As of 2026-09-16, Congleton Jon has 28 Form 4 transactions on record across 3 companies — 24 in the trailing 12 months.

Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.

Pattern in the record: open-market sales filed in July in multiple years since 2025 — a recurring calendar cadence, more consistent with scheduled activity than a one-off decision.

Reconstructed holdings

Direct: $17.8MIndirect: $0$17.8Mas of 2026-09-16
  • Direct $17.8M
  • Indirect $0
MLYSdirect603,621 sh$16.6M
AVLNdirect26,978 sh$936K
IMUXdirect25,370 sh$257K

Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.

Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.

Trades by company

MLYS · 25 trades
2026-07-13: Sale, 10,700 sh ($291K)2026-06-30: Sale, 58,000 sh ($1.5M)2026-06-30: Sale, 17,000 sh ($456K)2026-04-13: Sale, 15,730 sh ($422K)2026-03-31: Sale, 55,183 sh ($1.5M)2026-03-31: Sale, 19,364 sh ($494K)2026-03-31: Sale, 453 sh ($12K)2026-02-19: Award / grant, 187,900 sh ($0)2026-02-19: Award / grant, 140,900 sh ($0)2026-01-12: Sale, 9,119 sh ($294K)2026-01-12: Sale, 7,117 sh ($236K)2025-11-21: Option exercise, 24,082 sh ($13K)2025-11-21: Option exercise, 24,082 sh ($0)2025-11-11: Sale, 112,275 sh ($5.1M)2025-11-11: Sale, 32,850 sh ($1.5M)2025-11-11: Sale, 29,207 sh ($1.3M)2025-11-11: Sale, 12,806 sh ($533K)2025-11-11: Sale, 8,862 sh ($375K)2025-11-11: Sale, 4,000 sh ($174K)2025-10-13: Sale, 13,548 sh ($578K)2025-10-13: Sale, 1,552 sh ($67K)2025-07-11: Sale, 15,884 sh ($230K)2025-04-11: Sale, 15,319 sh ($187K)2025-02-13: Award / grant, 570,000 sh ($0)2025-01-13: Sale, 18,333 sh ($166K)
IMUX · 2 trades
2026-07-05: Award / grant, 25,370 sh ($0)2026-06-29: Award / grant, 50,740 sh ($0)
AVLN · 1 trade
2026-04-29: Award / grant, 26,978 sh ($0)

Filing ledger

DateCompanyActionShares @ priceValueOwnership ΔOwned afterFiling
2026-07-13MLYSSale10,700 @ $27.24$291K−1.7% of holding603,621Form 4
2026-06-30MLYSSale58,000 @ $25.94$1.5M−8.4% of holding631,321Form 4
2026-06-30MLYSSale17,000 @ $26.82$456K−2.7% of holding614,321Form 4
2026-04-13MLYSSale15,730 @ $26.83$422K−2.2% of holding689,321Form 4
2026-03-31MLYSSale55,183 @ $26.54$1.5M−7.3% of holding705,504Form 4
2026-03-31MLYSSale19,364 @ $25.50$494K−2.5% of holding760,687Form 4
2026-03-31MLYSSale453 @ $27.05$12K−0.1% of holding705,051Form 4
2026-01-12MLYSSale9,119 @ $32.21$294K−1.4% of holding646,268Form 4
2026-01-12MLYSSale7,117 @ $33.15$236K−1.1% of holding639,151Form 4
2025-11-11MLYSSale112,275 @ $45.83$5.1M−14.5% of holding664,155Form 4
2025-11-11MLYSSale32,850 @ $46.89$1.5M−4.9% of holding631,305Form 4
2025-11-11MLYSSale29,207 @ $45.20$1.3M−3.6% of holding776,430Form 4
2025-11-11MLYSSale12,806 @ $41.64$533K−1.5% of holding818,499Form 4
2025-11-11MLYSSale8,862 @ $42.31$375K−1.1% of holding809,637Form 4
2025-11-11MLYSSale4,000 @ $43.50$174K−0.5% of holding805,637Form 4
2025-10-13MLYSSale13,548 @ $42.63$578K−1.6% of holding832,857Form 4
2025-10-13MLYSSale1,552 @ $43.03$67K−0.2% of holding831,305Form 4
2025-07-11MLYSSale15,884 @ $14.51$230K−1.8% of holding846,405Form 4
2025-04-11MLYSSale15,319 @ $12.19$187K−1.7% of holding862,289Form 4
2025-01-13MLYSSale18,333 @ $9.06$166K−2.0% of holding877,608Form 4
8 award / exercise / gift records — not counted as purchases
DateCompanyActionSharesOwned afterFiling
2026-07-05IMUXAward / grant25,37025,370Form 4
2026-06-29IMUXAward / grant50,74050,740Form 4
2026-04-29AVLNAward / grant26,97826,978Form 4
2026-02-19MLYSAward / grant187,900187,900Form 4
2026-02-19MLYSAward / grant140,900780,051Form 4
2025-11-21MLYSOption exercise24,082655,387Form 4
2025-11-21MLYSOption exercise24,0820Form 4
2025-02-13MLYSAward / grant570,000570,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.